Literature DB >> 16203094

A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy.

Andrea G Hohmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16203094     DOI： 10.1016/j.pain.2005.07.007

Source DB:  PubMed          Journal:  Pain        ISSN： 0304-3959            Impact factor:   6.961


× No keyword cloud information.
  4 in total

1.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

2.  Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.

Authors:  Farinaz Nasirinezhad; Stanislava Jergova; James P Pearson; Jacqueline Sagen
Journal:  Neuropharmacology       Date:  2014-12-05       Impact factor: 5.250

3.  The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.

Authors:  Molly S Crowe; Catheryn D Wilson; Emma Leishman; Paul L Prather; Heather B Bradshaw; Matthew L Banks; Steven G Kinsey
Journal:  Br J Pharmacol       Date:  2017-11-20       Impact factor: 8.739

4.  The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.

Authors:  Liting Deng; Josée Guindon; V Kiran Vemuri; Ganesh A Thakur; Fletcher A White; Alexandros Makriyannis; Andrea G Hohmann
Journal:  Mol Pain       Date:  2012-09-22       Impact factor: 3.395
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.